Results for transġeniċi translation from Maltese to English

studji karċinoġenetiċi f’firien u ġrieden transġeniċi ma identifikawx xi potenzjal karċinoġenetiku.
carcinogenicity studies conducted in rats and transgenic mice did not identify any carcinogenic potential.

il-potenzjal karċinoġenu kien evalwat fi studju fuq firien li dam sentejn u fi studju fuq ġrieden transġeniċi li dam 6 xhur.
carcinogenic potential was assessed in a 2-year rat study and a 6-month transgenic mouse study.

studji fi ġrieden transġeniċi jissuġġerixxu potenzjal baxx ta ’ nutropin likwidu (mkabbar) li jistimola antikorpi.
studies in transgenic mice suggest a low antibody provoking potential of (aged) liquid nutropin.

thelin ma kienx karċinoġeniku meta ngħata lil firien għal 97-99 ġimgħa jew meta ngħata lil ġrieden transġeniċi p53(+/-) għal 6 xhur.
thelin was not carcinogenic when administered to rats for 97-99 weeks or when administered to p53(+/-) transgenic mice for 6 months.

nitisinone ma weriex potenzjal karċinoġeniku fi studju li dam 26 ġimgħa dwar riskju ta’ kanċer fi ġrieden transġeniċi (tgrash2).
nitisinone did not show carcinogenic potential in a 26-week carcinogenicity study in transgenic mice (tgrash2).

annimali transġeniċi (metodi ta’ ħolqien, karatterizzazzjoni ta’ ċelloli transġeniċi, natura tal-ġenu inserit)
transgenic animals (methods of creation, characterisation of transgenic cells, nature of the inserted gene)

ledipasvir ma kienx karċinoġeniku fl-istudju li dam 6 xhur dwar ġrieden transġeniċi rash2 f’esponimenti li kienu sa 26 darba ogħla mill-esponiment uman.
ledipasvir was not carcinogenic in the 6-month rash2 transgenic mouse study at exposures up to 26-fold higher than human exposure.

maraviroc ġie evalwat għall- potenzjal karċinoġeniku bi studju ta ’ 6 xhur fuq ġrieden transġeniċi u studju ta ’ 24 xahar fuq il- firien.
maraviroc was evaluated for carcinogenic potential by a 6 month transgenic mouse study and a 24 month study in rats.

antithrombin rikombinanti uman hu prodott fil-ħalib ta’ mogħoż transġeniċi permezz tat- teknoloġija rikombinanti tad-dna (rdna).
recombinant human antithrombin produced in the milk of transgenic goats by recombinant dna technology (rdna).

deferasirox ma żiedx ir- riskju tal-kanċer meta ngħata lill-firien fi studju ta’ sentejn u ġrieden eterożigi transġeniċi p53+/- fi studju ta’ 6 xhur.
deferasirox was not carcinogenic when administered to rats in a 2-year study and transgenic p53+/- heterozygous mice in a 6-month study.